De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
about
Oncolytic viruses as therapeutic cancer vaccinesRelevance of tumor-infiltrating lymphocytes in breast cancerTargeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityT-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modificationsTargeting the epigenome in malignant pleural mesotheliomaOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesEpigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancerHomeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth.Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.Expression of tumour-specific antigens underlies cancer immunoeditingA potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy.Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy.Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis.Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and KillingEngineering lymphocyte subsets: tools, trials and tribulationsEpigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implicationsInhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.Life after death: targeting high mobility group box 1 in emergent cancer therapies.Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responsesCombining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunityRecognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceEpigenetics in hepatocellular carcinoma: an update and future therapy perspectives.Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.The biology of cancer testis antigens: putative function, regulation and therapeutic potentialEpigenetics of melanoma: implications for immune-based therapies.
P2860
Q21245758-DB926914-6C35-40A0-BD68-C000A34E3E5DQ26795598-B94C4462-7CBE-4125-BC63-8CB2A17FB396Q26797280-D09B2104-EDCC-4790-8203-AB2F383EB3DDQ27335110-73308F1C-7187-4324-94FD-AFDF53EF6E5DQ33416734-244486CA-6558-4457-A7BF-D1B6CED065A4Q33884564-220DE5FD-2ABC-44F3-BCE8-BD7CCD2FC8D9Q33890546-4B36BBB6-FFC0-4255-897E-7C511358BAB5Q33924550-656B071B-23D3-4355-9E53-282647408C30Q33980682-1D4FE239-E74A-4BF1-8850-68C602566E1DQ34060948-42276BDE-AE96-4F43-8888-F0505C066004Q34182308-124EE702-15F1-4A40-98F8-88A29DE29A34Q34960346-897F7A9C-E379-4222-A1EA-CD789FF80758Q35050623-9ABE7631-70CA-4791-A94E-CBE15F094D19Q35074440-A7C1D917-553A-489B-A15F-DB685148AEB1Q35135031-21358AE0-4826-4B1C-9A9E-7796D7B01829Q35785378-3E4715EC-0FF3-48C2-9628-33FAAA54293FQ35968482-2FFEB95E-3665-45A0-92A5-62BDFCF4D823Q36056904-2DA030E5-0E45-41D4-8B14-5F1157357AB6Q36060324-7BA61FA9-00A4-4432-8C37-33E4B0BDFE55Q36067682-FAEFCEE8-3977-48EF-A04D-F71BA21B889BQ36118290-7440341D-4122-4595-B8EA-B11C5D5A1670Q36140986-422DA58E-1461-4D89-B591-A8F2B030E4DCQ36287972-AEABDCB9-D41E-4451-BB60-2E0E3F2EECF7Q36407481-AF6C20DF-C041-4B04-8020-3947C631DCA0Q36562901-52623F75-3526-41BB-9579-1DB762DB7F1AQ36786757-842D04AF-4402-4556-A981-442BA8937FDFQ36801625-2C5CB796-D98F-4827-A25C-3D9AB91F86DBQ36831746-5E798EAB-A480-46E8-9F34-FEEC7FAA7BBCQ37066925-851D0044-29A2-4C31-86E6-ECB1DC686623Q37142367-20EB332D-E0C8-4C1A-B4CF-4D3CCC9E6E42Q37197945-5D386A92-A6ED-470C-958C-DB6A8EFA6BDCQ37287152-E4AD01C1-0E08-46EA-8CE0-28F9BE2EB77EQ37581334-EB2F1F89-6DC5-4549-B698-584CA14EA4EEQ37585487-95308E1E-CCB2-4E6D-8A7D-E8993714954FQ37687307-5629F778-8CEA-4432-85E3-1AC9E810FC7EQ37729405-43E09E99-6C46-4F1E-824A-E0BDE22DEA97Q37731703-396EAD8A-90C9-47FC-BD5C-B527827A6B93Q37737327-3419B508-5AF1-4B7D-A062-06B9B856BAA0Q37849976-8FD07DA2-1860-4192-AE70-E5A27F0BF1CDQ38148588-2665FF37-12CD-4B45-9173-74286A72BEA3
P2860
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
De novo induction of a cancer/ ...... erapy in a murine tumor model.
@ast
De novo induction of a cancer/ ...... erapy in a murine tumor model.
@en
type
label
De novo induction of a cancer/ ...... erapy in a murine tumor model.
@ast
De novo induction of a cancer/ ...... erapy in a murine tumor model.
@en
prefLabel
De novo induction of a cancer/ ...... erapy in a murine tumor model.
@ast
De novo induction of a cancer/ ...... erapy in a murine tumor model.
@en
P2093
P2860
P1433
P1476
De novo induction of a cancer/ ...... herapy in a murine tumor model
@en
P2093
Dao M Nguyen
David S Schrump
G Aaron Chen
John R Wunderlich
Julie A Hong
Kari R Irvine
Paul J Spiess
Z Sheng Guo
P2860
P304
P356
10.1158/0008-5472.CAN-05-3020
P407
P577
2006-01-01T00:00:00Z